Coronavirus-Call der Innovative Medicines Initiative (IMI)

Die innovative medicines initiative (IMI) hat einen Förderaufruf zu Forschung im Zusammenhang mit COVID-19 herausgegeben:

Scope: Considering that this is a newly-identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

• development of antivirals as well as other types of therapeutics to address a rapid response to the current COVID-19 outbreak;
• development of therapeutics to address the current and/or future coronavirus outbreaks;
• development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies;
• development of fast and reliable tools that go beyond the state of the art for detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection.

Preventive vaccines are specifically excluded from the scope of the Call.

Als Budget von Seiten der IMI stehen 45 Millionen Euro zur Verfügung. Es handelt sich um ein schnelles, einstufiges Antragsverfahren (fast track, single-stage).

Projekte der IMI werden zur Hälfte von der Europäischen Kommission (über die IMI) und zur Hälfte als Eigenleistung von der Industrie finanziert.